Abstract
Background Parkinson’s disease is the second most common neurodegenerative disorder and affects people from all ethnic backgrounds, yet little is known about the genetics of Parkinson’s disease in non-European populations. In addition, the overall identification of copy number variants at a genome-wide level has been understudied in Parkinson’s disease patients.
Objectives To understand the genome-wide burden of copy number variants in Latinos and its association with Parkinson’s disease.
Methods We used genome-wide genotyping data from 747 Parkinson’s disease patients and 632 ancestry matched controls from the Latin American Research Consortium on the Genetics of Parkinson’s disease.
Results Genome-wide copy number burden analysis showed no difference between patients vs. controls, whereas patients were significantly enriched for copy number variants overlapping known Parkinson’s disease genes compared to controls (Odds Ratio: 3.97 [1.69 - 10.5], P = 0.018). PARK2 showed the strongest copy number burden, with 20 copy number variant carriers. These patients presented an earlier age of disease onset compared to patients with other copy number variants (median age at onset: 31 years vs. 57 years, P = 7.46 x 10-7).
Conclusions We found that Parkinson’s disease patients are significantly enriched with copy number variants affecting known Parkinson’s disease genes. We also identified that out of 250 patients with early-onset disease, 5.6% carried a copy number variant on PARK2 in our cohort. Our study is the first to analyze genome-wide copy number variants association in Latino Parkinson’s disease patients and provides insights about this complex disease in this understudied population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by a Stanley Fahn Junior Faculty Award from the Parkinson's Foundation and supported by a research grant from the American Parkinson's Disease Association, with resources and the use of facilities at the Veterans Affairs Puget Sound Health Care System.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by VA Puget Sound IRB, with the project name "LARGE-PD: Latin American Research Consortium of the Genetics of Parkinson's Disease", RDIS number: 0010, MIRB number: 00087. Currently, the study is under Cleveland Clinic IRB: 19-340.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data and methods are reported in the article and in the Supplement.